Biotechnology

Featured

A Bold Call on Biotech ETFs

By Todd ShriberMarch 26, 2015

Featured

Getting it Right (and Wrong) With Leveraged Biotech ETFs

By Todd ShriberMarch 25, 2015

Contributed

ETF Chart of the Day: Biotech Bonanza

By Paul Weisbruch, Street One FinancialMarch 23, 2015

Featured

Triple-Leveraged Biotech ETFs Could be Coming Soon

By Tom LydonMarch 20, 2015

Featured

Biogen Boosts Biotech ETFs to More New Highs

By Todd ShriberMarch 20, 2015

Featured

Where ETF Investors Have Been Putting All Their Money

By Tom LydonMarch 19, 2015

Featured

Biotech ETFs: Bring on Rising Rates

By Todd ShriberMarch 17, 2015

Featured

ETFs for the Next Biotech Takeover Targets

By Todd ShriberMarch 10, 2015

Featured

A Biotech ETF Right for Oncology Mergers and Acquisitions

By Todd ShriberMarch 9, 2015

Featured

Biotech ETFs Sholud Like AbbVie’s bid for Pharmacyclics

By Todd ShriberMarch 5, 2015

Featured

Familiar ETF Friend Will Enjoy a Pharmacyclics Sale

By Todd ShriberFebruary 26, 2015

Featured

Healthcare ETFs Have More Room to Run

By Tom LydonFebruary 11, 2015

Featured

This ETF Should Like the Intercept Pharma News

By Tom LydonJanuary 30, 2015

Featured

‘Tis the Season for Biotech ETFs

By Todd ShriberJanuary 5, 2015

Featured

Best Biotech ETF Gets a Lift From Merck’s Cubist Buy

By Tom LydonDecember 8, 2014

Featured

It Could be a Big December for Biotech ETFs

By Todd ShriberDecember 4, 2014

Featured

Short Covering Could be Next Catalyst for Health Care ETFs

By Todd ShriberNovember 24, 2014

Featured

A Biotech ETF Searches for New Highs

By Todd ShriberOctober 27, 2014

Previous 1 … 11 12 13 14 15 … 26 Next